| |
|
|
|
Summit Therapeutics plc  
|
|
3.08 -0.09 (-0.03%) |
07-10 16:00 |
|
Open: |
3.13 |
Pre close: |
3.17 |
Target:
|
3.95
|
|
High: |
3.185 |
Low: |
3.06 |
Resistance:
|
3.39
3.68
|
|
Volume: |
25,415 |
Market Cap: |
207M |
Support:
|
2.91
2.42
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
3.24
 |
MACD |
MACD(12,26):
|
-0.09 |
|
MA(20): |
3.29 |
Signal(12,26,9): |
-0.08 |
|
MA(100): |
2.98  |
Stochastic Oscillator |
%K(14,3):
|
42.00 |
|
MA(250): |
2.09 |
%D(3): |
50.80 |
|
Average Volume(K) |
3-Month: |
14218
|
52-Week |
High:
|
5.49 |
|
10-Days: |
6524 |
Low: |
1.18 |
|
RSI |
RSI(14):
|
40.32 |
Change(%): |
128.1 |
|
Financials, Statistics and Valuation |
|
EPS |
1.225 |
Return on Equity (ttm) |
0.0 |
Shares Out. (M) |
67.23 |
|
EPS Est. Current Year |
-0.530 |
Return on Assets (ttm) |
0.0 |
Shares Float (M) |
24.81 |
|
EPS Est. Next Year |
-1.050 |
PEG Ratio |
0.00 |
% Held by Insiders |
23.29 |
|
EPS Est. Next Quarter |
-0.620 |
Qtrly Rev. Growth |
-12.2 |
% Held by Institutions |
8.53 |
|
Forward EPS |
0.118 |
Gross Profit (p.s.) |
0.256 |
Shares Short (K) |
45 |
|
Book Value (p.s.) |
2.260 |
EBITDA (p.s.) |
0.000 |
P/E |
2.51 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
1.36 |
|
Profit Margin |
-142.60 |
Operating Cash Flow
(M) |
0.00 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
0.00 |
P/CF |
0.00 |
|
|
|
|
|
|
